Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy
Xingmeng Li,Shifeng Wei,Han Wu,Qiang Zhang,Zhigang Zhao,Shenghui Mei,Weixing Feng,Yun Wu,Mei, Shenghui,Feng, Weixing,Wu, Yun
DOI: https://doi.org/10.1007/s00431-023-05092-z
2023-07-27
European Journal of Pediatrics
Abstract:Oxcarbazepine (OXC) is an antiepileptic drug whose efficacy is largely attributed to its monohydroxy derivative metabolite (MHD). Nevertheless, there exists significant inter-individual variability in both the pharmacokinetics and therapeutic response of this drug. The objective of this study is to explore the impact of patients' characteristics and genetic variants on MHD clearance in a population pharmacokinetic (PPK) model of Chinese pediatric patients with epilepsy. The PPK model was developed using a nonlinear mixed effects modeling method based on 231 MHD plasma concentrations obtained from 185 children with epilepsy. The one-compartment model and combined residual model were established to describe the pharmacokinetics of MHD. Forward addition and backward elimination were employed to evaluate the impact of covariates on the model parameters. The model was evaluated using goodness-of-fit, bootstrap, visual predictive checks, and normalized prediction distribution errors. In the two final PPK models, age, estimated glomerular filtration rate (eGFR), and a combined genotype of six variants (rs1045642, rs2032582, rs7668282, rs2396185, rs2304016, rs1128503) were found to significantly reduce inter-individual variability for MHD clearance. The inter-individual clearance equals to 1.38 × (Age/4.74) 0.29 × (eGFR/128.66) 0.25 × e θ ABCB-UGT-SCN-INSR for genetic variants included model and 1.30 × (Age/4.74) 0.30 × (eGFR/128.66) 0.23 for model without genetic variants. The precision of all parameters was deemed acceptable, and the model exhibited good predictability while remaining stable and effective.
pediatrics